Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 28;77(11):2956-2959.
doi: 10.1093/jac/dkac245.

Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia

Roxane Rohani  1   2   3 , Marc H Scheetz  1   2   3 , Helen K Donnelly  4 , Alvaro Donayre  4 , Mengjia Kang  4 , Estefani Diaz  5 , Kay Dedicatoria  1 , Alan R Hauser  6   7 , Egon A Ozer  7 , Sophia Nozick  6 , Chao Qi  8 , Anna E Pawlowski  9 , Michael N Neely  10   11 , Alexander V Misharin  4 , Richard G Wunderink  4 , Nathaniel J Rhodes  1   2   3 ; NU SCRIPT Study investigators
Collaborators, Affiliations

Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia

Roxane Rohani et al. J Antimicrob Chemother. .

Abstract

Objectives: Critical illness reduces β-lactam pharmacokinetic/pharmacodynamic (PK/PD) attainment. We sought to quantify PK/PD attainment in patients with hospital-acquired pneumonia.

Methods: Meropenem plasma PK data (n = 70 patients) were modelled, PK/PD attainment rates were calculated for empirical and definitive targets, and between-patient variability was quantified [as a coefficient of variation (CV%)].

Results: Attainment of 100% T>4×MIC was variable for both empirical (CV% = 92) and directed (CV% = 33%) treatment.

Conclusions: Individualization is required to achieve suggested PK/PD targets in critically ill patients.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Individual meropenem plasma PK/PD attainment among patients treated for HAP. PK/PD target attainment stratified by target (blue = T>1×MIC, red = T>4×MIC) among patients treated empirically. Individual observations (open circles) are jittered to increase visual clarity where values overlap. The distribution of observed PK/PD ratios is shown in box plots, with overlaid density (half-eye) plots demonstrating the range and density of PK/PD ratios in the sample.
See this image and copyright information in PMC

References

    1. Kalil AC, Metersky ML, Klompas Met al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63: e61–111. - PMC - PubMed
    1. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41: 489–95. - PubMed
    1. Udy AA, De Waele JJ, Lipman J. Augmented renal clearance and therapeutic monitoring of β-lactams. Int J Antimicrob Agents 2015; 45: 331–3. - PubMed
    1. Ulldemolins M, Soy D, Llaurado-Serra Met al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother 2015; 59: 5520–8. - PMC - PubMed
    1. Kiffer CR, Mendes C, Kuti JLet al. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn Microbiol Infect Dis 2004; 49: 109–16. - PubMed

Publication types